FibroBiologics Doses First Patients in Phase 1/2 Trial for Diabetic Foot Ulcers
FBLG is trading near its 52-week low of $0.952 (13% above the low) on light trading volume (0.2× avg).
Summary
FibroBiologics has dosed the first patients in its Phase 1/2 clinical trial for Cywc628, a treatment for diabetic foot ulcers. This marks a positive step in the company's pipeline development, providing a much-needed R&D update amidst its severe financial distress. The company recently issued a going concern warning and is actively diluting shareholders through ATM offerings to fund operations.
At the time of this announcement, FBLG was trading at $1.08 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.5M. The 52-week trading range was $0.95 to $19.80. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.